Evidence map›Paper›PMID 35077149›Full record

ArticleACS infectious diseases2022

Quaternary Phosphonium Compounds: An Examination of Non-Nitrogenous Cationic Amphiphiles That Evade Disinfectant Resistance.

Kyle J Sommers, Marina E Michaud, Cody E Hogue, Amber M Scharnow, Lauren E Amoo, Ashley A Petersen, Robert G Carden, Kevin P C Minbiole, William M Wuest

Open access · greenAbstract read
In one paragraph

Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Highly Effective Biocides againstACS infectious diseases · 2024
    Article
  14. Article
  15. SynthesizedNanomaterials (Basel, Switzerland) · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Kyle J SommersDepartment of Chemistry, Villanova University, Villanova, Pennsylvania 19085, United States.
Marina E MichaudDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.
Cody E HogueDepartment of Chemistry, Villanova University, Villanova, Pennsylvania 19085, United States.
Amber M ScharnowDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.
Lauren E AmooDepartment of Chemistry, Villanova University, Villanova, Pennsylvania 19085, United States.
Ashley A PetersenDepartment of Chemistry, Villanova University, Villanova, Pennsylvania 19085, United States.
Robert G CardenDepartment of Chemistry, Villanova University, Villanova, Pennsylvania 19085, United States.
Kevin P C MinbioleDepartment of Chemistry, Villanova University, Villanova, Pennsylvania 19085, United States.ORCID 0000-0003-4263-9833
William M WuestDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.ORCID 0000-0002-5198-7744
Villanova University · USEmory University · US

Funding

Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Natural Product-Inspired Approaches Toward The Development Of Antivirulence And Species-Specific InhibitorsR35GM119426 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI William M Wuest · 2016 to 2026
$4.8M
NCATS NIH HHS UL1 TR000454NIGMS NIH HHS R35 GM119426
6 · The paper itself

Abstract

Quaternary ammonium compounds (QACs) serve as mainstays in the formulation of disinfectants and antiseptics. However, an over-reliance and misuse of our limited QAC arsenal has driven the development and spread of resistance to these compounds, as well as co-resistance to common antibiotics. Extensive use of these compounds throughout the COVID-19 pandemic thus raises concern for the accelerated proliferation of antimicrobial resistance and demands for next-generation antimicrobials with divergent architectures that may evade resistance. To this end, we endeavored to expand beyond canonical ammonium scaffolds and examine quaternary phosphonium compounds (QPCs). Accordingly, a synthetic and biological investigation into a library of novel QPCs unveiled biscationic QPCs to be effective antimicrobial scaffolds with improved broad-spectrum activities compared to commercial QACs. Notably, a subset of these compounds was found to be less effective against a known QAC-resistant strain of MRSA. Bioinformatic analysis revealed the unique presence of a family of small multiresistant transporter proteins, hypothesized to enable efflux-mediated resistance to QACs and QPCs. Further investigation of this resistance mechanism through efflux-pump inhibition and membrane depolarization assays illustrated the superior ability of P6P-10,10 to perturb the cell membrane and exert the observed broad-spectrum potency compared to its commercial counterparts. Collectively, this work highlights the promise of biscationic phosphonium compounds as next-generation disinfectant molecules with potent bioactivities, thereby laying the foundation for future studies into the synthesis and biological investigation of this nascent antimicrobial class.

Indexed as

COVID-19DisinfectantsDrug Resistance, BacterialHumansMicrobial Sensitivity TestsPandemicsSARS-CoV-2Disinfectantsantimicrobial resistancedisinfectantsQacCquaternary ammonium compounds (QACs)quaternary phosphonium compounds (QPCs)small multiresistant (SMR) family efflux pumps

Identifiers

PMID35077149
PMCPMC8996050
OpenAlexW4210540307

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.